Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: J Immunol. 2011 Feb 28;186(7):3977–3985. doi: 10.4049/jimmunol.1003588

Table 1.

Aggregate clinical data for VL patients and Endemic controls

VL (pre-treatinent)A VL (post-treatment) EC control spleen
n 100 39 29 10
Age 25.91 ± 15.2(25)B 27 ± 13.4(25) 33.5 ± 9.2(35) ND
Sex (M/F) 64/36 25/14 18/11 ND
Duration of illness (days) 24.3 ± 30.3(15) 27.2 ± 23.2(20) N/A NA
Infection scoreC Day 0 2 ± 1.1(2) 1.92 ± 1(2) N/A N/A
Day dis 0 0 NA NA
N/A N/A
Spleen size (cm) Day 0 4.8 ± 3.9(3) 4.8 ± 3.3(4)
Day dis 0.57 ± 1.3 0.8 ± 1.6 N/A N/A
WBC(X103/mm3) Day 0 3.2 ± 1.3(3) 3.1 ± 0.9(3) ND ND
Day dis 7 ± 2.3(7) 6.3 ± 2.1(6.2) ND N/A

N/D, not done: N/A, not applicable.

A

Includes 39 donors from whom post-treatment samples were also available

B

Mean values ± SD of aggregated data are shown, median values are in parenthesis.

C

Scoring of parasite load is on a logarithmic scale from 1 to 6, were 0 is no parasites per 1,000 microscopic fields (1,000X), 1 is 1–10 parasites per 1,000 fields, and 6 is >100 parasites per field.